Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Jeffrey William Henderson, a director at Becton Dickinson & Co (NYSE:BDX), recently acquired 1,500 shares of the company's common stock. The purchase, which took place on February 10, 2025, was made ...

In a regulatory filing, Becton Dickinson (BDX) disclosed that its director Jeffrey Henderson bought 1.5K shares of common stock on February ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...

Becton Dickinson Announces Strategic Business Separation Plan BD sees FY25 adjusted EPS $14.30-$14.60 vs. previous view $14.25-$14.60 Becton Dickinson to separate biosciences, diagnostic solutions ...

Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.